Related Experiment Videos

Combined antihypertensive and lipid-lowering treatment

Maurizio Cesari1, Achille C Pessina

  • 1Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padova, via Giustiniani, 2, 35126 Padova, Italy. mcesari@hotmail.com

Current Hypertension Reports
|July 20, 2004
PubMed

Insights

Treating high blood pressure (hypertension) and high cholesterol (hypercholesterolemia) together is recommended to lower cardiovascular risk. This review evaluates evidence on combined treatments for better heart health outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Hypertension and hypercholesterolemia frequently coexist and significantly increase cardiovascular risk.
  • Despite guidelines recommending treatment, low rates of diagnosis and control persist, contributing to high cardiovascular disease burden.
  • Combined treatment strategies are increasingly investigated for improved patient outcomes.

Purpose of the Study:

  • To critically evaluate the evidence supporting combined antihypertensive and lipid-lowering therapies.
  • To assess the benefits of combined treatment on endothelial function, atherosclerosis, and cardiovascular event prevention.

Main Methods:

  • Systematic review and critical evaluation of recent (past 5 years) clinical studies.
  • Analysis of data on endothelial dysfunction, coronary atherosclerosis progression, and hypertension control.
  • Assessment of primary and secondary cardiovascular event prevention data.

Main Results:

  • Evidence suggests potential benefits of combined therapy on endothelial function and atherosclerosis.
  • Combined treatment may improve hypertension control and reduce cardiovascular events.
  • Further research is ongoing to solidify these findings and optimize treatment protocols.

Conclusions:

  • Combined antihypertensive and lipid-lowering treatment shows promise in managing cardiovascular risk.
  • Addressing both hypertension and hypercholesterolemia concurrently is crucial for effective cardiovascular prevention.
  • The reviewed evidence supports further investigation and potential clinical adoption of combined therapeutic approaches.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...